Consequently, the downregulation of WNT5A observed in PTSO-treated mice may not only indicate suppression of proliferative signaling, but also a direct impairment of CSC maintenance, potentially lowering the risk of tumor recurrence and therapy resistance. Here, WNT5A is linked to neoplasm.